The PPAR-γ agonist rosiglitazone attenuates PQ-induced pulmonary fibrosis by upregulating PTEN and decreasing the expression of TGF-β1 in a PPAR-γ-dependent manner [104]. The gene discussed is PTEN; the disease is pulmonary fibrosis.